Phathom Pharmaceuticals Statistics
Want to see PHAT full AI Analyst Report?
Phathom Pharmaceuticals (PHAT) Stock Statistics & Valuation Metrics
Total Valuation
Phathom Pharmaceuticals has a market cap or net worth of $442.63M. The enterprise value is $990.61M.
- Market Cap
- $442.63M
- Enterprise Value
- $990.61M
Share Statistics
Phathom Pharmaceuticals has 81,291,520 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 81,291,520
- Owned by Insiders
- 8.84%
- Owned by Institutions
- 47.87%
Financial Efficiency
Phathom Pharmaceuticals’s return on equity (ROE) is 0.50 and return on invested capital (ROIC) is -125.23%.
- Return on Equity (ROE)
- 0.50
- Return on Assets (ROA)
- -0.85
- Return on Invested Capital (ROIC)
- -125.23%
- Return on Capital Employed (ROCE)
- -1.26
- Revenue Per Employee
- 471.99K
- Profits Per Employee
- -596.35K
- Employee Count
- 371
- Asset Turnover
- 0.68
- Inventory Turnover
- 4.10
Valuation Ratios
The current PE Ratio of Phathom Pharmaceuticals is -6.10. Phathom Pharmaceuticals’s PEG ratio is -0.04.
- PE Ratio
- -6.10
- PS Ratio
- 1.86
- PB Ratio
- 0.00
- Price to FCF
- -24.26
- Price to Operating Cash Flow
- -25.71
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Phathom Pharmaceuticals had revenue of 175.11M and earned -221.25M in profits. Earnings per share was -3.03.
- Revenue
- 175.11M
- Gross Profit
- 152.51M
- Operating Income
- -159.99M
- Pretax Income
- -221.25M
- Net Income
- -221.25M
- EBITDA
- -152.50M
- Earnings Per Share (EPS)
- -3.03
Cash Flow
In the last 12 months, operating cash flow was -20.74M and capital expenditures -302,000, giving a free cash flow of -21.04M billion.
- Operating Cash Flow
- -20.74M
- Free Cash Flow
- -21.04M
- Free Cash Flow per Share
- -0.25
Dividends & Yields
Phathom Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.12%
- Earnings Yield
- -15.57%
Stock Price Statistics
- Beta
- 2.34
- 52-Week Price Change
- -56.27%
- 50-Day Moving Average
- 7.32
- 200-Day Moving Average
- 10.17
- Relative Strength Index (RSI)
- 49.53
- Average Volume (3m)
- 1.43M
Important Dates
Phathom Pharmaceuticals upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Phathom Pharmaceuticals as a current ratio of 1.73, with Debt / Equity ratio of -48.34%
- Current Ratio
- 1.73
- Quick Ratio
- 1.69
- Debt to Market Cap
- 0.17
- Net Debt to EBITDA
- -0.54
- Interest Coverage Ratio
- -2.35
Taxes
In the past 12 months, Phathom Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Phathom Pharmaceuticals EV to EBITDA ratio is -24.92, with an EV/FCF ratio of -23.47.
- EV to Sales
- 1.80
- EV to EBITDA
- -24.92
- EV to Free Cash Flow
- -23.47
- EV to Operating Cash Flow
- -23.82
Balance Sheet
Phathom Pharmaceuticals has $184.56M in cash and marketable securities with $167.96M in debt, giving a net cash position of $16.60M billion.
- Cash & Marketable Securities
- $184.56M
- Total Debt
- $167.96M
- Net Cash
- $16.60M
- Net Cash Per Share
- $0.20
- Tangible Book Value Per Share
- -$4.10
Margins
Gross margin is 80.68%, with operating margin of -9.26%, and net profit margin of -30.19%.
- Gross Margin
- 80.68%
- Operating Margin
- -9.26%
- Pretax Margin
- -30.19%
- Net Profit Margin
- -30.19%
- EBITDA Margin
- -7.21%
- EBIT Margin
- -7.38%
Analyst Forecast
The average price target for Phathom Pharmaceuticals is $16.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $16.90
- Price Target Upside
- 169.11% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 86.75%
- EPS Growth Forecast
- 72.98%
Scores
- Smart Score
- 4
- AI Score
- 50
